YAMAMOTO Masaki

写真a

Affiliation

School of Medicine, Department of Pediatrics

Job title

Associate Professor

Professional Memberships 【 display / non-display

  •  
     
     

    JAPAN PEDIATRIC SOCIETY

  •  
     
     

    THE JAPANESE SOCIETY OF HEMATOLOGY

  •  
     
     

    THE JAPANESE SOCIETY OF PEDIATRIC HEMATOLOGY / ONCOLOGY

  •  
     
     

    日本造血細胞移植学会

Research Areas 【 display / non-display

  • Life sciences   Fetal medicine/Pediatrics   小児血液学

 

Research Interests 【 display / non-display

  • GVHD

  • luekemia

  • hematopoietic stem cell transplantation

  • pediatric cancer

Papers 【 display / non-display

  • Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an <i>ATIC–ALK</i> gene fusion

    Yusuke Akane, Masaki Yamamoto, Akira Takebayashi, Ryo Hamada, Keita Igarashi, Makoto Emori, Shintaro Sugita, Kohichi Takada, Tadashi Hasegawa, Takeshi Tsugawa

    Pediatric Blood &amp; Cancer ( Wiley )   2024.06

    DOI

  • Impact of BRAF/MEK inhibitor on BRAF V600E-mutated pilocytic astrocytoma.

    Ryo Hamada, Yusuke Akane, Yukinori Akiyama, Kohichi Takada, Masaki Yamamoto

    Pediatrics international : official journal of the Japan Pediatric Society   65 ( 1 ) e15653  2023  [International journal]

    DOI PubMed

  • Multiple lung lesions in a 13-year-old girl with classical nodular sclerosis Hodgkin Lymphoma.

    Shuhei Adachi, Akira Takebayashi, Kotoe Iesato, Keita Igarashi, Masaki Yamamoto, Tsukasa Hori, Yukihiko Kawasaki, Taijiro Mishina, Shintaro Sugita

    International journal of hematology   113 ( 3 ) 318 - 319  2021.03  [Domestic journal]

    DOI PubMed

  • Familial Mediterranean Fever After Cord Blood Transplantation for Familial Hemophagocytic Lymphohistiocytosis.

    Keita Igarashi, Tsukasa Hori, Masaki Yamamoto, Naoki Hatakeyama, Kotoe Iesato, Akira Takebayashi, Toshitaka Kizawa, Takako Miyamae, Manabu Kawamoto, Yukihiko Kawasaki

    Journal of pediatric hematology/oncology    2021.02  [International journal]

     View Summary

    Familial Mediterranean fever (FMF) is a hereditary autoinflammatory disorder accompanied by periodic fever and sterile serositis. We report a 5-year-old boy with FMF, who underwent second unrelated cord blood transplantation (CBT) for recurrent familial hemophagocytic lymphohistiocytosis. Periodic attacks of fever and abdominal pain started 6 months after CBT. He was diagnosed with FMF according to the Tel-Hashomer criteria and treated successfully with colchicine. Genetic testing showed heterozygous p.E148Q mutation in the MEFV gene from both donor and recipient cells. Several CBT-related factors including use of an immunosuppressant can potentially be involved in the pathogenesis of FMF in our patient.

    DOI PubMed

  • A SARS-CoV-2-positive patient coincidentally diagnosed with B-ALL.

    Masaki Yamamoto, Yusuke Akane, Keita Igarashi, Tsukasa Hori, Yukihiko Kawasaki

    Pediatrics international : official journal of the Japan Pediatric Society   63 ( 2 ) 221 - 223  2021.02  [International journal]

    DOI PubMed

display all >>

Misc 【 display / non-display

  • Chemokine CCL8 as a diagnostic marker of acute graft-versus-host disease (GVHD)

    山本 雅樹, 堀 司, 太田 明伸

    血液・腫瘍科 ( 科学評論社 )  60 ( 4 ) 484 - 492  2010.04

    CiNii

  • A diagnostic marker of acute graft-versus-host disease (GVHD): chemokine CCL8

    山本 雅樹, 堀 司, 鈴木 信寛

    The Journal of clinical pediatrics,Sapporo ( 小児愛育協会 )  57 ( 5 ) 77 - 86  2009.12

    CiNii

  • Potential biomarker discovery in graft-versus-host disease (GVHD)

    堀 司, 苗代 康可, 相馬 仁, 鈴木 信寛, 畠山 直樹, 山本 雅樹, 園田 智子, 水江 由佳, 今井 浩三

    札幌医学雑誌 ( 札幌医科大学 )  77 ( 1 ) 7 - 12  2008.12

     View Summary

    Although graft-versus-host disease (GVHD) is a life- threatening complication of hematopoietic stem cell transplantation (HSCT), current diagnosis mainly depends on clinical manifestations and invasive biopsies. Specific biomarkers for GVHD would facilitate early and accurate recognition of this grave condition. Using a proteomic approach, we screened for plasma proteins specific for GVHD in a mouse model. One peak with 8,972 m/z retained a discriminatory value in two diagnostic groups (GVHD and normal controls) with increased expression in the disease, decreased expression during cyclosporin A treatment and was barely detectable in syngeneic transplantation. Purification and mass analysis identified this molecule as CCL8, a member of a large chemokine family. In human samples, the serum concentration of CCL8 correlated closely with GVHD severity. All non-GVHD samples had low levels of CCL8. In sharp contrast, CCL8 was highly up-regulated in GVHD sera. CCL8 is a promising specific serum marker for the early and accurate diagnosis of GVHD.

    DOI CiNii

  • Double high-dose chemotherapy with autologous peripheral blood stem cell transplantation for a patient with relapsed Wilms' tumor

    山本 雅樹, 鈴木 信寛, 水江 伸夫

    The Journal of clinical pediatrics,Sapporo ( 小児愛育協会 )  55 ( 3 ) 57 - 62  2007.08

    CiNii

  • An aplastic crisis and haemophagocytic syndrome caused by parvovirus B19 infection

    十川 稲子, 山本 雅樹, 畠山 直樹

    The Journal of clinical pediatrics,Sapporo ( 小児愛育協会 )  55 ( 3 ) 77 - 80  2007.08

    CiNii

display all >>

Research Projects 【 display / non-display

  • 学童期から思春期の子どもの小児がん医療における意思形成過程の解明と支援方法の開発

    基盤研究(C)

    Project Year :

    2021.04
    -
    2024.03
     

    道信 良子, 山本 雅樹, 五十嵐 敬太

     View Summary

    学童期に小児がんを発症した子どもたちが、自分に対する医療や自分の身体に対してどのような過程を経て、自分の小児がん医療に対する意思を形成していくのかを明らかにするために、臨床における短い参与観察とインフォーマル・インタビューを行った。5歳から12歳までに小児がんを発症し、半年以上の入院生活を経験している子ども12人を対象とした。新型コロナウイルス感染症の予防のため、子どもと面会する時間は15分以内とし、面会が禁止されている期間はカルテからの情報を得た。面会が解除されたら、医師の回診にも付き添い、子どもと医療者とのかかわりを観察した。以上の継続的な焦点化した調査をふまえて、小児がん医療に学際的な子ども学の視点を取り入れ、小児がん医療における子どもの意思決定を支援していくための理論的枠組を検討した。それは、子どもの成長と医師の育みを視野にいれながら、子どもと周囲の人との「関係性」に着目した意思決定である。この結果は、国際小児がん学会に抄録としてまとめ、提出した。現在査読中である。方法論の検討は十分に進んでいないが、新型コロナウイルス感染症対策もふまえ、斬新な方法が必要であり、研究に参加している家族の意向をたずねている。なお、地域の参与観察( 子どもと家族が住んでいる地域での催しや行事に許可を得て参加すること)も、感染症対策の観点から遠隔での調査を現在検討している。学校における健康づくりや身体のケアに関する子どもの意思決定とその支援の現状についても、次年度に検討したい。

  • CCL8制御で介入した移植片対宿主病における病態解析の基礎的研究

    基盤研究(C)

    Project Year :

    2021.04
    -
    2024.03
     

    五十嵐 敬太, 山本 雅樹, 赤根 祐介, 浜田 亮

     View Summary

    ドナーとしてC57BL/6(B6)マウス(H-2b, I-Ab)、レシピエントとしてBALB/cマウス(H-2d, I-Ad)を使用し、レシピエントマウスにドナーマウスの骨髄細胞と脾臓細胞を移植することで致死的急性移植片対宿主病(GVHD)を誘導した。 ドナーがB6-野生型(WT)でレシピエントがBALB/c-WTマウスの移植群と、ドナーがB6-CCL8ノックアウト(CCL8KO)マウスでレシピエントが同じくBALB/c-WTの移植群のアウトカムを比較した。移植後の体重減少に有意差はなく、移植後day1とday4のELISA測定による末梢血のCCL8発現も同等であった。両移植群ともに移植後day7までには全例早期死亡し、log-rank検定では生存率に差を認めなかった。 結果から、ドナーのCCL8欠損は重症GVHDを誘導する移植モデルでは生存率に影響を与えないことが示唆された。

  • Pathological analysis of acute graft-versus-host disease and development of molecular targeted therapy for acute GVHD

    Grant-in-Aid for Scientific Research (C)

    Project Year :

    2015.04
    -
    2018.03
     

    Yamamoto Masaki

     View Summary

    We performed mixed leukocyte reaction assay using wild type and CCL8-knockout mice. CCL8 protein were not detected in the supernatant of CCL8 KO mice. Also we preformed RNA interference assay with ccl8 specific siRNA. By the RNAi, CCL8 protein were slightly decreased in the supernatant. Thus, gene manipulation maybe the treatment option of acute GVHD To explore the role of Chemokine (C-C motif) ligand 8 (CCL8) as a potential biomarker for acute graft-versus-host disease (aGVHD), we retrospectively analyzed the sera and clinical course of 31 patients with grade II to IV aGVHD. No deaths occurred in the ten patients with serum CCL8 concentrations less than 213 pg/mL, whereas 11 of the 21 patients with more than 213 pg/mL died within 180 days post-transplantation. Thus, elevated serum CCL8 concentration before day 100 post-transplantation may predict aGVHD prognosis.

  • Analysis of molecular function of CCL8 as a biomarker for acute graft-versus-host disease

    Grant-in-Aid for Young Scientists (B)

    Project Year :

    2010
    -
    2011
     

    YAMAMOTO Masaki

     View Summary

    We studied about chemokine CCL8 as a biomarker of acute graft-versus-host disease(GVHD). The plasma CCL8 concentration in GVHD mouse model showed correlated with the severity and the prognosis of GVHD mice. Similarly, serum CCL8 concentration may reflect the response to the treatment against GVHD and correlate with the severity of GVHD in human.

  • Development of the quantitative method and the analysis of function of the molecular marker for acute graft-versus-host disease.

    Grant-in-Aid for Young Scientists (B)

    Project Year :

    2008
    -
    2009
     

    YAMAMOTO Masaki

     View Summary

    We studied about chemokine CCL8 as a biomarker of acute graft-versus-host disease (GVHD). We developed ELISA for plasma CCL8 level in the GVHD mouse models. We analyzed the expression mechanism of CCL8 using in vitro and in vivo model.

display all >>